Guggenheim Increases Zevra Therapeutics (NASDAQ:ZVRA) Price Target to $22.00

Zevra Therapeutics (NASDAQ:ZVRA) had its price target upped by analysts at Guggenheim from $20.00 to $22.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim’s price target would indicate a potential upside of 183.72% from the stock’s current price.

A number of other research firms have also recently issued reports on ZVRA. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Zevra Therapeutics in a report on Thursday. Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 price target on shares of Zevra Therapeutics in a research report on Wednesday. Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a research note on Wednesday. Finally, Canaccord Genuity Group dropped their price target on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $21.86.

Zevra Therapeutics Price Performance

ZVRA stock traded down $0.17 during mid-day trading on Thursday, hitting $7.75. The company had a trading volume of 257,733 shares, compared to its average volume of 410,567. Zevra Therapeutics has a 12-month low of $4.20 and a 12-month high of $9.76. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The company has a 50-day moving average price of $7.95 and a 200 day moving average price of $8.14. The company has a market capitalization of $413.88 million, a price-to-earnings ratio of -3.93 and a beta of 1.98.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.28). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The business had revenue of $12.00 million for the quarter, compared to the consensus estimate of $8.93 million. On average, research analysts anticipate that Zevra Therapeutics will post -1.95 earnings per share for the current year.

Insider Buying and Selling at Zevra Therapeutics

In other Zevra Therapeutics news, CFO R. Laduane Clifton sold 11,000 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $86,460.00. Following the completion of the transaction, the chief financial officer now directly owns 51,361 shares of the company’s stock, valued at approximately $403,697.46. The trade was a 17.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Neil F. Mcfarlane sold 61,273 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $481,605.78. Following the completion of the sale, the chief executive officer now owns 222,060 shares in the company, valued at approximately $1,745,391.60. This represents a 21.63 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 85,773 shares of company stock valued at $674,176. 2.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets purchased a new stake in shares of Zevra Therapeutics during the 4th quarter worth about $53,000. China Universal Asset Management Co. Ltd. acquired a new position in Zevra Therapeutics in the 4th quarter worth about $94,000. XTX Topco Ltd purchased a new position in Zevra Therapeutics during the third quarter worth approximately $94,000. Intech Investment Management LLC acquired a new stake in Zevra Therapeutics in the third quarter valued at approximately $95,000. Finally, Squarepoint Ops LLC grew its holdings in Zevra Therapeutics by 36.1% in the fourth quarter. Squarepoint Ops LLC now owns 16,534 shares of the company’s stock valued at $138,000 after purchasing an additional 4,384 shares during the period. Hedge funds and other institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.